Recent posts

From the Results of Yesterday to the Biologic Drugs of Tomorrow

By April 11, 2018

A thousand small delays and opportunities for error can snowball over the years of a complex biotherapeutic drug development program. They add up to lost time and increased risk in an endeavor that has little tolerance for either. It doesn’t have to be this way.

Categories: Pharmaceutical
Tags: , , , ,

Biosimilars Intensify the Need for Harmonized Data

By February 28, 2018

To get the most out of recent innovations in biopharma development and QC such as multi-attribute monitoring, it’s time to better connect the systems that manage biopharma data. This series explores the what, the why, and the how of better biopharma data.

Categories: Pharmaceutical
Tags: , , , ,

Biopharma Data: Chaos or Harmony?

By January 29, 2018

If data can throw your biotherapeutic development program into chaos, it can also help move you forward. Let’s see how.

Categories: Pharmaceutical
Tags: , , , , , , , ,

Three Reasons for Biopharmaceutical Labs to Add Mass Detection to Routine Analyses

By March 9, 2016

As regulators focus in on the critical quality attributes of biotherapeutics, what can biopharmaceutical labs in late development or QC do to increase confidence in their bioseparations – other than to run more assays?

Categories: Pharmaceutical, Technologies
Tags: , , , , , , , , , , , , , , , , , , , ,

Multiple Attribute Monitoring of Biopharmaceuticals Using Mass Detection

By September 3, 2015

Multiple attribute monitoring has become a hot topic of discussion within biopharmaceutical organizations as the methodology allows detection and measurement of more critical quality attributes than conventional methods. Waters recently sponsored an outstanding webinar on… Read more >

Categories: Pharmaceutical, Technologies
Tags: , , ,